category,datetime,headline,id,image,related,source,summary,url
company,1768946973,How Recent Developments Are Shaping The RxSight (RXST) Investment Story,138190987,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MS,Yahoo,"Why the fair value estimate on RxSight just nudged higher Analysts recently inched their fair value estimate on RxSight stock from about US$10.33 to about US$10.39 per share, a small move that still signals a subtle shift in how the story is being framed. Behind this tweak are updated model assumptions, including a slightly different discount rate input of about 7.73% and revenue growth now set at about 3.37%, informed by recent quarters that some researchers describe as better than they had...",https://finnhub.io/api/news?id=15762511142aa578be9d03d79b88b2fe692b67950b3db52d6c7447c3cf35a0ec
company,1768929005,Why Analysts Say Akamai Technologies (AKAM) Story Is Shifting Toward Security Compute And AI,138188520,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MS,Yahoo,"The recent shift in Akamai Technologies' fair value estimate to US$101.16 from US$95.20 reflects updated assumptions around how its push into security, compute, and AI infrastructure might influence the long term outlook. With the discount rate trimmed to 10.21% and revenue growth now modeled at 6.99%, the revised target remains in the same ballpark as recent Street work that clusters around the US$100 to US$115 range, but still embeds a mix of optimism and caution about the investment needed...",https://finnhub.io/api/news?id=ed476061e08b753bb728d511368e5baac9936736c222104de23269ab0952d498
company,1768928185,"Vertical Software Well Positioned to Monetize AI Growth, Morgan Stanley Says",138188521,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MS,Yahoo,Vertical software companies with wide proprietary industry data sets and end-to-end platforms are we,https://finnhub.io/api/news?id=11cd247444f5b0e7dd6ef57e51d9929f327f74cff371f6bb5b694b5e613fc474
company,1768927500,Participation notifications by Morgan Stanley,138188522,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MS,Yahoo,"Press release Regulated information Brussels, January 20, 2026, 17:45 CET In line with Belgian transparency legislation (Law of May 2, 2007), Morgan Stanley recently sent to Solvay the following transparency notifications indicating that they crossed the threshold of 3%. Here is a summary of the notifications: Date on which the threshold is crossedVoting rights after the transactionEquivalent financial instruments after the transactionTotalDecember 23, 20250.00%-0.00%January 9, 20260.04%3.16%3.2",https://finnhub.io/api/news?id=69d313fa70c7f8d65a0f6ebcd681b8b58d3645b54a8724c5c1aa7e434ad3f6c7
company,1768926720,Morgan Stanley stock underperforms Tuesday when compared to competitors,138208427,,MS,MarketWatch,Morgan Stanley stock underperforms Tuesday when compared to competitors,https://finnhub.io/api/news?id=e55e098ca5dda36113cdad8ca393773bfdcbbf8f6ab00d970f3e063272ff0d1d
company,1768926352,Why Hims & Hers Health (HIMS) Stock Is Down Today,138188523,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MS,Yahoo,Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 2.2% in the morning session after Morgan Stanley reiterated its Equalweight rating but voiced concerns about the company's slowing growth and increasing competition.,https://finnhub.io/api/news?id=69c4ee41c9e98bafaa42806dbd91b2d46554946e53980f7271d8d454beffe62f
company,1768925729,Morgan Stanley sees improving fundamentals driving small-cap outperformance,138188524,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MS,Yahoo,"Investing.com -- Morgan Stanley told clients in a recent note that improving fundamentals continue to support small-cap equity outperformance, even as the market pares back expectations for Federal Reserve rate cuts this year.",https://finnhub.io/api/news?id=7baf14200e4aec06344e7a007d15d5f598a6b6226a3f446e0bc33f64be9314db
company,1768923985,"Celanese's Q4 Earnings Likely to Hit Low End of Guidance Amid Acetyl Margin Pressure, Morgan Stanley Says",138187493,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MS,Yahoo,Celanese's (CE) earnings per share for Q4 of 2025 is expected to be at the low end of its guidance d,https://finnhub.io/api/news?id=61ff73b397419ce5563fa2964abf4f18a613f6425ca3ce84d982f8c08491a75f
company,1768917600,Morgan Stanley Real Estate Investing Acquires San Francisco Bay Area Advanced Manufacturing Facility for $110 Million,138187494,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MS,Yahoo,"NEW YORK, January 20, 2026--Morgan Stanley Investment Management, through funds managed by Morgan Stanley Real Estate Investing (MSREI), announced today the acquisition of a premier advanced manufacturing property in Fremont, California, for $110 million, which is subject to a long-term net lease with Western Digital, a global leader in the data storage and infrastructure solutions sector.",https://finnhub.io/api/news?id=98b4b760c4ab25cf1d264c02f2d78c58037011f7ede9496475a073150bb8f5cb
company,1768908160,US IT hardware stocks fall as Morgan Stanley turns cautious on sector,138185707,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MS,Yahoo,"U.S. IT hardware stocks fell on Tuesday after Morgan Stanley downgraded its view on the ​industry, warning that companies could drastically reduce their spending ‌budgets as enterprise demand slows and component costs rise. U.S.-listed shares of Logitech ‌and NetApp dropped 6.2% and about 3.8% respectively in premarket trading after the Wall Street brokerage slashed its rating on both companies to ""underweight"" from ""equal-weight"". Morgan Stanley reduced its rating on CDW Corporation to ""equal-weight"" ⁠from ""overweight"", sending its shares ‌down 2.1%.",https://finnhub.io/api/news?id=8c08d6f2ce8922f0aa16fb0737f316204cc33bdd045a29d84cf40c74683c98f9
company,1768907051,How Recent Analyst Shifts Are Rewriting The Story For Clorox (CLX),138185697,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MS,Yahoo,"Clorox’s latest price target work reflects a slightly more cautious base case, with fair value trimmed from about US$122.41 to US$119.76 as analysts balance mixed views on volume, pricing, and earnings quality. The discount rate and long term revenue growth assumptions are essentially steady, but modestly softer expectations for the top line and earnings power have been enough to nudge the fair value estimate lower rather than higher. If you are following the stock, it is worth staying tuned...",https://finnhub.io/api/news?id=ae528bfcde2e1d77c2f17c2f00a559d0e8ee849766652c86e4ea6d11b81c03df
company,1768906918,"Morgan Stanley (MS)’s CEO is Doing a Great Job, Says Jim Cramer",138185709,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MS,Yahoo,We recently published 15 Fresh Stocks Jim Cramer Discussed. Morgan Stanley (NYSE:MS) is one of the stocks Jim Cramer discussed. Morgan Stanley (NYSE:MS) is one of the largest investment banks in the world. The shares are up by 37% over the past year and by 3.9% year-to-date. Keefe Bruyette raised the share price target to […],https://finnhub.io/api/news?id=381c292b185dd4fcd716af428e8f4877aec794fc441626a990206468f8fc7f89
company,1768906425,Akamai Technologies’ Quarterly Earnings Preview: What You Need to Know,138186473,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MS,Yahoo,"Akamai Technologies is poised to release its fourth-quarter results next month, with analysts anticipating a modest single-digit decline in earnings.",https://finnhub.io/api/news?id=f5aa346cbda09a62b174c1f2387db34a25e20d638de3972015772b71a4ee9c06
company,1768867861,Looking At The Narrative For Alector (ALEC) After Latozinemab Setback And Cost Cuts,138181945,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,MS,Yahoo,"The fair value estimate for Alector has shifted slightly, moving from 2.05 to 2.10, while the discount rate has also adjusted from 7.54% to 7.39%, even as the revenue growth assumption remains anchored to about a 50.08% decline. This reflects a recalibrated view after mixed Street research, where cautious ratings, the failed latozinemab Phase 3 trial, and a pipeline reset sit alongside cost cuts and remaining pipeline options that some investors still factor into their thinking. Continue with...",https://finnhub.io/api/news?id=3414be98e8abfd27cbe26af3e829a9c65d9d72ba4f33baa1ce14831287d6b6e8
